Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;14(12):4571-4573.
doi: 10.21037/jtd-2022-21.

Characterizing thymic tumors-how to track down rare diseases

Matthias Lang  1 , Thomas Pausch  1 , Chrysanthi Anamaterou  2
Affiliations
Editorial

Characterizing thymic tumors-how to track down rare diseases

Matthias Lang et al. J Thorac Dis. 2022 Dec.
No abstract available

Keywords: Thymic tumors; prognostic factors; rare disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2022-21/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Ferreira CR. The burden of rare diseases. Am J Med Genet A 2019;179:885-92. 10.1002/ajmg.a.61124 - DOI - PubMed
    1. Orphanet. (2018). Prevalence and incidence of rare diseases: Bibilographic data. Diseases listed by decreasing prevalence, incidence or number of published cases (Orphanet Report Series No. Number 2). Available online: http://www.orpha.net/orphacom/cahiers/docs/GB/P
    1. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren. Neuroendocrine Neoplasia within the German NET Registry. Z Gastroenterol 2018;56:1237-46. 10.1055/a-0661-6099 - DOI - PubMed
    1. Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2017;18:1652-64. - PubMed
    1. Lang M, Hackert T, Anamaterou C. Long-term effect of everolimus in recurrent thymic neuroendocrine neoplasia. Clin Endocrinol (Oxf) 2021;95:744-51. 10.1111/cen.14572 - DOI - PubMed